Clinical Effect of Tislelizumab Combined with Albumin Paclitaxel and Carboplatin in the Treatment of Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer

ZHANG Jing; YANG Meilin

doi:10.14033/j.cnki.cfmr.2025.07.013

Abstract：Objective:To analyze the clinical effect of Tislelizumab combined with Albumin Paclitaxel and Carboplatin in the treatment of stage Ⅲb-Ⅳ non-small cell lung cancer(NSCLC).Method:A total of 102 patients with stage Ⅲb-Ⅳ NSCLC who admitted to Sir Run Run Hospital Nanjing Medical University from January 2020 to March 2024 were selected as the study objects,and they were divided into the control group and the observation group according to random number table method,with 51 cases in each group.The control group was given Albumin Paclitaxel combined with Carboplatin,the observation group was given Tislelizumab on the basis of the control group.The short-term efficacy,serum tumor marker levels and adverse reactions were compared between two groups.Result:The objective remission rate(ORR)and clinical control rate(DCR)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment(CYFRA21-1)and squamous cell carcinoma antigen(SCC)in two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05);there was no significant differences in the incidence of adverse reactions between two groups during treatment(P>0.05).Conclusion:Tislelizumab combined with Albumin Paclitaxel and Carboplatin in the treatment of stage Ⅲb-Ⅳ NSCLC patients can improve the short-term clinical effect,reduce the level of serum tumor markers,and does not increase adverse drug reactions.